Dr. Reddy's Laboratories (Dr. Reddy's Laboratories) announced on May 21 that the subsidiary and the Icelandic biotech company Alvotech have reached an internal license agreement for the registration and commercialization of the biosimilar product “Denosumab” developed by Alvotech. Reddy Pharmaceuticals will obtain registration and commercialization rights for the biosimilar drug “Denosumab” developed by Alvotech, and that Reddy Pharmaceuticals will obtain exclusive agency rights in the US market.
瑞迪制药获Denosumab在美独家代理权
Reddy Pharmaceuticals obtains exclusive agency rights for Denosumab in the US
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.